These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34133478)

  • 41. Psychosocial interventions for preventing and treating depression in dialysis patients.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Rabindranath KS; Strippoli GF
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD004542. PubMed ID: 31789430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis.
    Gu Y; Yang X; Liang H; Li D
    BMC Gastroenterol; 2019 Dec; 19(1):231. PubMed ID: 31888534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.
    Maneeton N; Maneeton B; Suttajit S; Reungyos J; Srisurapanont M; Martin SD
    Drug Des Devel Ther; 2014; 8():1685-93. PubMed ID: 25336914
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.
    Mohammed OS; Attia HG; Mohamed BMSA; Elbaset MA; Fayed HM
    J Pharm Pharm Sci; 2023; 26():11808. PubMed ID: 38022905
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of emricasan on chronic liver diseases: current data.
    Lekakis V; Cholongitas E
    Clin J Gastroenterol; 2022 Apr; 15(2):271-285. PubMed ID: 35000120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ursodeoxycholic acid for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis.
    Mu LY; Li SQ; Tang LX; Li R
    Clinics (Sao Paulo); 2021; 76():e2409. PubMed ID: 34133478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emricasan for the treatment of liver cirrhosis: a meta-analysis of randomized controlled trials.
    Jie Y; Youchun L; Jingxiang C
    Afr Health Sci; 2023 Jun; 23(2):402-408. PubMed ID: 38223578
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
    Frenette CT; Morelli G; Shiffman ML; Frederick RT; Rubin RA; Fallon MB; Cheng JT; Cave M; Khaderi SA; Massoud O; Pyrsopoulos N; Park JS; Robinson JM; Yamashita M; Spada AP; Chan JL; Hagerty DT
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):774-783.e4. PubMed ID: 29913280
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
    J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C-Treated Liver Transplant Recipients With Residual Fibrosis or Cirrhosis.
    Weinberg EM; Curry MP; Frenette CT; Regenstein FG; Schiff ER; Goodman ZD; Robinson JM; Chan JL; Imperial JC; Reddy KR
    Liver Transpl; 2021 Apr; 27(4):568-579. PubMed ID: 33164276
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.